AI assistant
EKF DIAGNOSTICS HOLDINGS PLC Director's Dealing 2021
7617_dirs_2021-04-30_af4657da-242d-487d-9d47-31d82c3d0dea.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 2901X
EKF Diagnostics Holdings PLC
30 April 2021
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Director Dealing
The Board of EKF Diagnostics Holdings plc (AIM: EKF) has been informed that on 30 April 2021 Adam Reynolds, Non-Executive Director, sold a total of 500,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 73.05 pence per Ordinary Share.
Following this transaction, Adam Reynold's total direct and indirect interest in the Group is 1,168,613 Ordinary Shares representing approximately 0.26% of the Group's total issued share capital.
The Notification of Dealing Form required in accordance with UK MAR is set out below.
| EKF Diagnostics Holdings plc | www.ekfdiagnostics.com | |
| Christopher Mills, Non-executive Chairman | Tel: +44 (0) 29 2071 0570 | |
| Julian Baines, CEO | ||
| Richard Evans, FD & COO | ||
| N+1 Singer | Tel: 020 7496 3000 | |
| Aubrey Powell / George Tzimas (Corporate Finance) Tom Salvesen (Corporate Broking) |
||
| Walbrook PR Limited | Tel: +44 (0) 20 7933 8780 or [email protected] | |
| Paul McManus / Lianne Cawthorne | Mob: +44 (0) 7980 541 893 / +44 (0) 7584 391 303 | |
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries. EKF specialises in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analysers.
EKF specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the USA for a variety of life science products.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Adam Reynolds | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Non-Executive Director | |||
| b) | Initial notification /Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | EKF Diagnostics Holdings plc | |||
| b) | LEI | 213800DXTF3EAUK1AR05 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.01 each | |||
| Identification code | GB0031509804 | ||||
| b) | Nature of the transaction | Sale of Ordinary Shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) (pence) | Volume(s) | ||||
| 73.05 | 500,000 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | N/A - Single Transaction | ||||
| - Price | |||||
| e) | Date of the transaction | 30 April 2021 | |||
| f) | Place of the transaction | London Stock Exchange - AIM |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBSGDSISXDGBG